In times of National Emergency such as the Covid Pandemic, the US Government has to spend $ Trillions to save health, jobs and the overall economy thereby endangering the financial recovery . This also increases the National Debt. However, the path out of any health crisis rests solely with scientific research to find cures. Many promising but vulnerable biotech startups struggle against unnecessary financial headwinds created by individuals and financial organizations betting on the short side thereby diverting difficult to raise capital to their own bottom line, waisting countless time and efforts by delaying - if not annihilating- scientific breakthroughs and most of all spooking potential investors.
This has led in the past to spectacular failures of viable biotech projects and is not in the interest of public health . It also acts as a big brake in the country’s scientific competitiveness.
We therefore propose a total ban on shorting of biotech startups under a project named the ´Biotech Investment Protection Act’ BIPA under which any biotech startup company under 10 years of age and/or with a market cap below a predetermined amount would be protected from any kind of shorting activity.
This act would have several benefits : It would protect seed investments in fundamental research, it would bolster scientific activity, it would improve National Health and increase National Security by lowering the National Debt.
This project is in the best interest of We, the People of the United States of America .